Subscribe
Home
Issues
2023
February 2023 - Vol 16 No 1
2022
December 2022 - Vol 15 No 6
October 2022 - Vol 15 No 5
August 2022 - Vol 15 No 4
June 2022 - Vol 15 No 3
April 2022 - Vol 15 No 2
February 2022 - Vol 15 No 1
2021
December 2021 - Vol 14 No 6
October 2021 - Vol 14 No 5
August 2021 - Vol 14 No 4
June 2021 - Vol 14 No 3
April 2021 - Vol 14 No 2
February 2021 - Vol 14 No 1
Issue Archive
Special Issues
Supplements
ASK THE EXPERT:
First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer: Checkmate 9LA
Guide to New FDA Approvals
2021 Year in Review
Multiple Myeloma
Advances in Dual Immunotherapy Cancer Treatments
Ovarian Cancer
HER2-Negative Breast Cancer
Triple-Negative Breast Cancer
Renal-Cell Carcinoma
Biosimilars
Gastrointestinal Cancer
Non–Small-Cell Lung Cancer
Categories
Conference Correspondent
ASCO 2021 - Breast Cancer
ASCO 2020 - Lung Cancer
ASH 2019 Wrap-Up
ASH 2019 MM
Web Exclusives
Gastrointestinal Cancer Monthly Minutes
Interview with the Innovators
Drug Updates
Media Library
Videos
Audiocasts
Ask the Experts
Master Class Series
Podcasts
Quick Quiz
CE
Lymphoma
Zanubrutinib Superior to Ibrutinib in Patients with Relapsed or Refractory CLL/SLL
By
Patricia Stewart
ASH 2022
,
Leukemia
,
Lymphoma
,
Hematologic Malignancies
TON - February 2023 Vol 16, No 1
A head-to-head phase 3 clinical trial in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) has found that zanubrutinib (Brukinsa), a next-generation Bruton tyrosine kinase (BTK) inhibitor, was more effective at preventing disease progression and is better tolerated than ibrutinib (Imbruvica), a first-generation BTK inhibitor that is the current standard of care for this population of patients.
Read More ›
Targeted Therapy with Brentuximab Vedotin Reduces Relapse Risk in Pediatric Patients with High-Risk Hodgkin Lymphoma
In the Literature
,
Lymphoma
TON - December 2022 Vol 15, No 6
Standard pediatric chemotherapy regimens used in the treatment of children and adolescents with high-risk Hodgkin lymphoma are often associated with late effects, including second cancers, infertility, and cardiovascular disease, as well as significantly reduced overall survival (OS).
Read More ›
CAR T-Cell Therapies May Improve Outcomes in Relapsed/Refractory Large B-Cell Lymphoma
ASH
,
Lymphoma
TON - February 2022 Vol 15, No 1
The results from 2 phase 3 clinical trials highlighted the superiority of CAR T-cell therapies over current standard of care (SOC) when used earlier in the course of treatment for patients with large B-cell lymphoma (LBCL).
Read More ›
November 25, 2019 – Oncology News & Updates
FDA Updates
,
In the News
,
Leukemia
,
Lung Cancer
,
Lymphoma
Web Exclusives
Calquence Receives FDA Approval for the Treatment of Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Despite Some Positive Trends, Report Confirms Lung Cancer Remains the Deadliest Form of Cancer
Read More ›
November 18, 2019 — Oncology News & Updates
Drug Updates
,
FDA Updates
,
Hepatocellular Carcinoma
,
In the News
,
Lymphoma
Web Exclusives
Teva Will Resume Production of Vincristine in Response to Shortage
FDA Fast-Tracks Opdivo plus Yervoy Regimen for Treatment of Advanced Liver Cancer
FDA Grants Accelerated Approval to Brukinsa for Patients with Mantle-Cell Lymphoma
Read More ›
Umbralisib Shows Encouraging Results in Relapsed or Refractory Marginal-Zone Lymphoma
By
Phoebe Starr
Lymphoma
TON - June 2019, Vol 12, No 3
Atlanta, GA—The investigational PI3K inhibitor umbralisib had encouraging activity as monotherapy in patients with relapsed or refractory marginal-zone lymphoma in an analysis of the phase 2 UNITY-NHL trial. Interim results were presented at the 2019 American Association for Cancer Research (AACR) meeting.
Read More ›
Copiktra (Duvelisib) Approved for Relapsed or Refractory CLL, SLL, and Follicular Lymphoma
By
Lisa A. Raedler, PhD, RPh, Medical Writer
FDA Updates
,
Lymphoma
2019 Fourth Annual Oncology Guide to New FDA Approvals
Chronic lymphocytic leukemia (CLL) is a cancer of B-cell lymphocytes and is the most common type of leukemia in adults. More than 20,000 Americans were diagnosed with CLL in 2018.
Read More ›
Imbruvica (Ibrutinib) plus Rituxan (Rituximab) New Combination Approved for the Treatment of Waldenström’s Macroglobulinemia
By
Lisa A. Raedler, PhD, RPh, Medical Writer
FDA Updates
,
Lymphoma
2019 Fourth Annual Oncology Guide to New FDA Approvals
In 1944, Jan G. Waldenström, MD, published his observations about a series of patients who presented with anemia, hepatosplenomegaly, hyperviscosity, bleeding, lymphoplasmacytic infiltrate in the bone marrow, and a large serum protein or “macroglobulin.”
1
Today, Waldenström’s macroglobulinemia, also known as lymphoplasmacytic lymphoma, a type of non-Hodgkin lymphoma, is classified as a rare, indolent, and heterogeneous type of lymphoma of the lymphatic system.
Read More ›
Calquence (Acalabrutinib) Approved for Relapsed or Refractory Mantle-Cell Lymphoma in Adults
By
Lisa A. Raedler, PhD, RPh, Medical Writer
FDA Updates
,
Lymphoma
2018 Third Annual Oncology Guide to New FDA Approvals
Mantle-cell lymphoma is a rare and fast-growing type of non-Hodgkin lymphoma (NHL), comprising approximately ≥4% of NHL cases in the United States. Mantle-cell lymphoma most often affects men aged ≥60 years, and the key factors affecting prognosis include the patient’s age, performance status, lactate dehydrogenase levels, and white blood cell count.
Read More ›
Imbruvica (Ibrutinib) First Drug Approved Specifically for Marginal-Zone Lymphoma and for Chronic Graft-versus-Host Disease
By
Lisa A. Raedler, PhD, RPh, Medical Writer
FDA Updates
,
Lymphoma
2018 Third Annual Oncology Guide to New FDA Approvals
Marginal-zone lymphoma (MZL) arises from B-lymphocytes in the marginal zone of lymphoid tissue. This slow-growing indolent B-cell lymphoma represents approximately 12% of all cases of non-Hodgkin lymphoma (NHL) in adults. MZL is divided into 3 subtypes, including mucosa-associated lymphoid tissue (MALT), nodal MZL, and splenic MZL. MALT lymphoma is the most common of these subtypes and occurs in the stomach, intestines, salivary glands, thyroid, eyes, and lungs. In MALT lymphoma, autoimmune processes or chronic infection cause B-cells to accumulate.
Helicobacter pylori
is 1 of at least 6 microbial species associated with lymphoproliferation in gastric MALT lymphoma.
Read More ›
Page 1 of 2
1
2
View the Latest Issue of TON
Read Issue
Home
Issues
2023
February 2023 - Vol 16 No 1
2022
December 2022 - Vol 15 No 6
October 2022 - Vol 15 No 5
August 2022 - Vol 15 No 4
June 2022 - Vol 15 No 3
April 2022 - Vol 15 No 2
February 2022 - Vol 15 No 1
2021
December 2021 - Vol 14 No 6
October 2021 - Vol 14 No 5
August 2021 - Vol 14 No 4
June 2021 - Vol 14 No 3
April 2021 - Vol 14 No 2
February 2021 - Vol 14 No 1
Issue Archive
Special Issues
Supplements
ASK THE EXPERT:
First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer: Checkmate 9LA
Guide to New FDA Approvals
2021 Year in Review
Multiple Myeloma
Advances in Dual Immunotherapy Cancer Treatments
Ovarian Cancer
HER2-Negative Breast Cancer
Triple-Negative Breast Cancer
Renal-Cell Carcinoma
Biosimilars
Gastrointestinal Cancer
Non–Small-Cell Lung Cancer
Categories
Conference Correspondent
ASCO 2021 - Breast Cancer
ASCO 2020 - Lung Cancer
ASH 2019 Wrap-Up
ASH 2019 MM
Web Exclusives
Gastrointestinal Cancer Monthly Minutes
Interview with the Innovators
Drug Updates
Media Library
Videos
Audiocasts
Ask the Experts
Master Class Series
Podcasts
Quick Quiz
CE
Subscribe Today!
To sign up for our newsletter or print publications, please enter your contact information below.
I'd like to receive:
TON
Print Edition
TON
Weekly e‑Newsletter
-- Please Select --
Afghanistan
Åland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia, Plurinational State of
Bonaire, Sint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Congo, the Democratic Republic of the
Cook Islands
Costa Rica
Côte d'Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and McDonald Islands
Holy See (Vatican City State)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran, Islamic Republic of
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People's Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia, the former Yugoslav Republic of
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia, Federated States of
Moldova, Republic of
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory, Occupied
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Russian Federation
Rwanda
Saint Barthélemy
Saint Helena, Ascension and Tristan da Cunha
Saint Kitts and Nevis
Saint Lucia
Saint Martin (French part)
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Sint Maarten (Dutch part)
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan, Province of China
Tajikistan
Tanzania, United Republic of
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela, Bolivarian Republic of
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
I have reviewed and consent to the terms of
TON
's
Privacy Policy
, and
TON
has my permission to retain my information in its database, and to forward pertinent communications to me.
START YOUR SUBSCRIPTION